Bora-Pharmaceuticals-Header Bora-Pharmaceuticals-Header


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type


            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Human Monoclonal Antibody

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CERC-002

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Cerecor

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 29, 2021


            CERC-002 is a first-in-class anti-LIGHT monoclonal antibody. LIGHT is homologous to lymphotoxin and exhibits an inducible expression. It competes with the HSV glycoprotein D for binding to the herpesvirus entry mediator, a receptor expressed on T lymphocytes.